Hemodynamic and cardiovascular effects of nitric oxide modulation in the therapy of septic shock

Pharmacotherapy

Volumn 20, Issue 10 I, 2000, Pages 1184-1197

  Schoonover, L L ^a   Stewart, A S ^a   Clifton, G D ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR;

CARDIOVASCULAR RESPONSE; CROSS LINKING; DRUG EFFECT; ENZYME INDUCTION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HEMODYNAMIC MONITORING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEPTIC SHOCK; SOCIOECONOMICS; TRANSCRIPTION REGULATION; VASCULAR SMOOTH MUSCLE;

EID: 0033781773     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.15.1184.34587     Document Type: Review

References (99)

1. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU group for severe sepsis
2. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit
3. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis
4. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever
5. Treating patients with severe sepsis
6. Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy
7. Sepsis and nitric oxide
8. Shock
9. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
10. Nitric oxide as a secretory product of mammalian cells
11. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rates
12. Nitric oxide: An endogenous modulator of leukocyte adhesion
13. Nitrogen oxide levels in patients after trauma and during sepsis
14. Clinical biology of nitric oxide
15. Nitric oxide in septic shock: Directions for future therapy?
16. Nitric oxide in the nervous system
17. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitrosocompounds
18. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures
19. Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases
20. Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells
21. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: An insight into endotoxin shock
22. Endothelium-derived relaxing factor and coronary vasospasm
23. Flow induced release of endothelium-derived relaxing factor
24. The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action
25. Cyclic guanosine monophosphate enhanced sequestration of Ca2+ by sarcoplasmic reticulum in vascular smooth muscle
26. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle
27. 2+, and mechanical transients in canine gastric smooth muscle
28. Effects of nitric oxide/EDRF on platelet surface glycoproteins
29. NO donors prevent integrin-induced leukocyte adhesion but not P-selectin dependent rolling in postischemic venules
30. Inhibition of nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and an oxygen radical-mediated hepatic injury
31. New insights into the regulation of inducible nitric oxide synthesis
32. The role of nitric oxide in sepsis - An overview
33. Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide
34. Microstatic effect of murine macrophages for Toxoplasma gondii: Role of synthesis of inorganic nitrogen oxides from L-arginine
35. Nitric oxide and inflammatory arthritides
36. Nitric oxide in the gut
37. Induction of nitric oxide synthase in the neointima induced by a periarterial collar in rabbits
38. Nitric oxide and septic shock
39. Antimicrobial and immunopathologic effects of cytokine-induced nitric oxide synthase
40. Kinetics of superoxide dismutase and iron catalyzed nitration of phenolics by peroxynitrite
41. Sensitivity of the essential zinc-thiolate moiety of yeast alcohol dehydrogenase to hypochlorite and peroxynitrate
42. Examining the oxidative chemistry of peroxynitrite
43. Inflammation, immunoregulation, and inducible nitric oxide synthase
44. Endothelin-1 and blood pressure after inhibition of nitric oxide synthesis in human septic shock
45. L-Arginine: Nitric oxide pathway in endotoxemia and human septic shock
46. Nitric oxide in the pathogenesis of vascular disease
47. Nitric oxide and nitric oxide-generating compounds inhibits hepatocyte protein synthesis
48. Elevated plasma levels of endothelin in patients with sepsis syndrome
49. Endothelin production in sepsis and the adult respiratory distress syndrome
50. Protective and pathological roles of nitric oxide in endotoxin shock
51. Therapeutic strategies for the inhibition of inducible nitric oxide synthase - Potential for a novel class of anti-inflammatory agents
52. Design of isoform-selective inhibitors of nitric oxide synthase
53. Nitric oxide in the pathogenesis of sepsis
54. Nonselective versus selective inhibition of inducible nitric oxide synthase in experimental endotoxic shock
55. Association of microvascular leakage with induction of nitric oxide synthase: Effects of nitric oxide synthase inhibitors in various organs
56. Pharmacokinetics of the nitric oxide synthase inhibitor L-N(G)-methylarginine hydrochloride in patients with septic shock
57. Effect of L-NAME, an inhibitor of nitric oxide synthesis, on plasma levels of IL-6, IL-8, TNFα and nitrite/nitrate in human septic shock
58. Effect of L-NAME, an inhibitor of nitric oxide synthesis, on cardiopulmonary function in human septic shock
59. Effect of nitric oxide inhibitor, L-N(G)-monomethylarginine, on accumulation of interleukin-6 and interleukin-8, and nuclear-kβ activity in a human endothelial cell line
60. Nitric oxide synthase inhibition by L-NAME in leukocytopenic patients with severe septic shock
61. Effects of a nitric oxide synthase inhibitor in humans with septic shock
62. Distribution and metabolism of N(G)-nitro-L-arginine methyl ester in patients with septic shock
63. Effects of L-canavanine, an inhibitor of inducible nitric oxide synthase, on endotoxin mediated shock in rats
64. Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/dysfunction, caused by endotoxin
65. Potent and selective inhibition of human nitric oxide synthases
66. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo
67. Selective inhibition of inducible nitric oxide synthase: Effects of hemodynamics and regional blood flow in healthy and septic sheep
68. Pharmacological characterization of guanidinoethyldisulphide (GED), a novel inhibitor of nitric oxide synthase with selectivity towards the inducible isoform
69. Beneficial effects of mercaptoethylguanidine, an inhibitor of the inducible isoform of nitric oxide synthase and a scavenger of peroxynitrite, in a porcine model of delayed hemorrhagic shock
70. 2-Iminohomopiperidinium salts as selective inhibitors of inducible nitric oxide synthase (iNOS)
71. Supplemental L-arginine HCl augments bacterial phagocytosis in human polymorphonuclear leukocytes
72. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility
73. L-Arginine pathway in the sepsis syndrome
74. The nitric oxide pathway in glomerulonephritis
75. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality
76. Prevention of lethality and suppression of proinflammatory cytokines in experimental septic shock by microencapsulated CNI-1493
77. Tetrahydrobiopterin and GTP cyclohydrolase I in a rat model of endotoxic shock: Relation to nitric oxide synthesis
78. Clinical applications of nitric oxide
79. Methylene blue inhibits nitrovascular and endothelium derived relaxing factor induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells by generation of superoxide anion
80. Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock
81. Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: Role of inhibition of NFkB activation
82. Linomide administration to mice attenuates the induction of nitric oxide synthase elicited by lipopolysaccharide-activated macrophages and prevents nephritis in MRL/Mp-Ipr/Ipr Mice
83. Linomide, a novel immunomodulator that prevents death in four models of septic shock
84. Glucocorticoid regulation of nitric oxide and tetrahydrobiopterin in a rat model of septic shock
85. A controlled trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock
86. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis
87. A new nitric oxide scavenger, imidazolineoxyl N-oxide derivative and its effects in pathophysiology and microbiology
88. Hemoglobin-based blood substitutes: Oxygen carriers, pressor agents or oxidants?
89. L-Arginine and endothelin receptor antagonist bosentan counteract hemodynamic effects of modified hemoglobin
90. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: Lessons learned from experimental and clinical studies
91. Pulmonary hypertension and reduced cardiac output during inhibition of nitric oxide synthesis in human septic shock
92. The nitric oxide synthase inhibitor 546C88 promotes the resolution of shock in patients with severe sepsis
93. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock
94. Multi-center randomized placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock
95. Use of methylene blue in patients with refractory septic shock: Impact on hemodynamics and gas exchange
96. Methylene blue administration in septic shock: A clinical trial
97. Methylene blue increases myocardial function in septic shock
98. Short term effects of methylene blue on hemodynamic and gas exchange in humans with septic shock
99. Vasopressor effects of diaspirin cross-linked hemoglobin (DCLHb) in critically ill patients